These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88. Use of monoclonal antibodies in renal transplantation. van den Hoogen MW; Hilbrands LB Immunotherapy; 2011 Jul; 3(7):871-80. PubMed ID: 21751955 [TBL] [Abstract][Full Text] [Related]
89. Desensitization with plasmapheresis and anti-Cd20 for ABO incompatible kidney transplantation from living donor: experience of a single center in Italy. Silvestre C; Furian L; Marson P; Tison T; Valente M; Marchini F; Rossi B; Bonfante L; Valerio F; Cozzi E; Rigotti P Transplant Proc; 2014 Sep; 46(7):2209-13. PubMed ID: 25242753 [TBL] [Abstract][Full Text] [Related]
90. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen. Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938 [TBL] [Abstract][Full Text] [Related]
91. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab. Budde K; Bosmans JL; Sennesael J; Zeier M; Pisarski P; Schütz M; Fischer W; Neumayer HH; Glander P Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741 [TBL] [Abstract][Full Text] [Related]
92. Bortezomib in kidney transplant recipients with antibody mediated rejection: three case reports. Wong W; Lee RA; Saidman SL; Smith RN; Zorn E Clin Transpl; 2009; ():401-5. PubMed ID: 20524305 [TBL] [Abstract][Full Text] [Related]
93. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165 [TBL] [Abstract][Full Text] [Related]
94. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Hippen BE; DeMattos A; Cook WJ; Kew CE; Gaston RS Am J Transplant; 2005 Sep; 5(9):2248-52. PubMed ID: 16095505 [TBL] [Abstract][Full Text] [Related]
95. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Levi ME; Quan D; Ho JT; Kleinschmidt-Demasters BK; Tyler KL; Grazia TJ Clin Transplant; 2010; 24(2):223-8. PubMed ID: 19659514 [TBL] [Abstract][Full Text] [Related]
96. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Theruvath TP; Saidman SL; Mauiyyedi S; Delmonico FL; Williams WW; Tolkoff-Rubin N; Collins AB; Colvin RB; Cosimi AB; Pascual M Transplantation; 2001 Jul; 72(1):77-83. PubMed ID: 11468538 [TBL] [Abstract][Full Text] [Related]
97. Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. Baran DA; Lubitz S; Alvi S; Fallon JT; Kaplan S; Galin I; Correa R; Courtney MC; Chan M; Spielvogel D; Lansman SL; Gass AL Transplant Proc; 2004 Dec; 36(10):3164-6. PubMed ID: 15686719 [TBL] [Abstract][Full Text] [Related]
98. Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis. Sawada T; Fuchinoue S; Teraoka S Transplantation; 2002 Nov; 74(9):1207-10. PubMed ID: 12451255 [TBL] [Abstract][Full Text] [Related]